Indication
Haemophilus influenzae type b infection
*Haemophilus influenzae* type b infection is a bacterial disease caused by the encapsulated, Gram-negative coccobacillus *Haemophilus influenzae* serotype b. Read more about Haemophilus influenzae type b infection
42 drugs 31 manufacturers
Drugs that treat it
Common Haemophilus influenzae type b infection therapies.
CEFTRIAXONE (ceftriaxone sodium)
CEFTRIAXONE IN DEXTROSE,ISO-OS (ceftriaxone sodium in iso-osmotic dextrose)
CEFTRIAXONE (ceftriaxone sodium)
CEFTRIAXONE (ceftriaxone sodium)
CLAFORAN (cefotaxime sodium)
CEFTRIAXONE (ceftriaxone sodium)
CEFTRIAXONE (ceftriaxone sodium)
CEFTRIAXONE (ceftriaxone sodium)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soon*Haemophilus influenzae* type b infection is a bacterial disease caused by the encapsulated, Gram-negative coccobacillus *Haemophilus influenzae* serotype b.
It predominantly affects infants and young children under five years of age, as well as immunocompromised or asplenic adults, following nasopharyngeal colonization and subsequent mucosal or hematogenous dissemination.
Pathophysiologically driven by its polyribosylribitol phosphate capsule, which evades phagocytosis, the pathogen can cause localized mucosal illness or progress to life-threatening invasive diseases, characteristically manifesting as acute bacterial meningitis, epiglottitis, bacteremic pneumonia, septic arthritis, and purulent bacteremia.
- nih.gov
*Haemophilus influenzae* type b infection is a bacterial disease caused by the encapsulated, Gram-negative coccobacillus *Haemophilus influenzae* serotype b Pathophysiologically driven by its polyribosylribitol phosphate capsule, which evades phagocytosis, the pathogen can cause localized mucosal illness or progress to life-threatening invasive diseases, characteristically manifesting as acute bacterial meningitis, epiglottitis, bacteremic pneumonia, septic arthritis, and purulent bacteremia
- medlineplus.gov
It predominantly affects infants and young children under five years of age, as well as immunocompromised or asplenic adults, following nasopharyngeal colonization and subsequent mucosal or hematogenous dissemination
- medlineplus.gov
It predominantly affects infants and young children under five years of age, as well as immunocompromised or asplenic adults, following nasopharyngeal colonization and subsequent mucosal or hematogenous dissemination Pathophysiologically driven by its polyribosylribitol phosphate capsule, which evades phagocytosis, the pathogen can cause localized mucosal illness or progress to life-threatening invasive diseases, characteristically manifesting as acute bacterial meningitis, epiglottitis, bactere...
- cdc.gov
It predominantly affects infants and young children under five years of age, as well as immunocompromised or asplenic adults, following nasopharyngeal colonization and subsequent mucosal or hematogenous dissemination
Personalize your experience
Follow Haemophilus influenzae type b infection and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.